SpliceBio Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Private

  • Employees
  • 39

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 7

SpliceBio General Information

Description

Operator of a biotechnology company intended to develop genetic medicines through Protein Splicing gene therapy. The company's platform allows addressing of adeno-associated viruses, both by increasing the size of the cargo gene that can be delivered and by expanding the range of tissues that can be targeted and further used to treat patients that suffer from incurable genetic diseases, thereby helping clients to develop and produce biotherapeutics that overcome the limitations of natural inteins.

Contact Information

Website
www.splice.bio
Formerly Known As
ProteoDesign
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Discovery Tools (Healthcare)
Drug Discovery
Corporate Office
  • Parc Científic de Barcelona (PCB)
  • Baldiri Reixac, 10
  • 08028 Barcelona
  • Spain
+34 934 00 00 00

SpliceBio Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

SpliceBio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Secondary Transaction - Private 000.00 Completed Generating Revenue
7. Later Stage VC (Series A) 16-Feb-2022 000.00 000.00 000.00 Completed Generating Revenue
6. Grant 10-Dec-2020 00000 00.000 Completed Pre-Clinical Trials
5. Seed Round 22-Jun-2020 00.000 00.000 00.000 Completed Pre-Clinical Trials
4. Early Stage VC 12-Dec-2017 00.000 00.000 Completed Pre-Clinical Trials
3. Seed Round 20-Apr-2015 00000 00000 00.000 Completed Pre-Clinical Trials
2. Seed Round 13-Dec-2014 Completed Pre-Clinical Trials
1. Spin-Off 01-Jan-2012 Completed Startup
To view SpliceBio’s complete valuation and funding history, request access »

SpliceBio Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary 000,000 00.000000 00.00 00.00 00 00.00 00.000
Ordinary 00,000 00.000000 000.00 000.00 00 000.00 0.000
Ordinary 44,243 $1.118140 $16.76 $16.76 1x $16.76 8.79%
To view SpliceBio’s complete cap table history, request access »

SpliceBio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biotechnology company intended to develop genetic medicines through Protein Splicing gene therapy. The com
Biotechnology
Barcelona, Spain
39 As of 2024
000.00
000000 - 000 000.00

000000

se cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non
0000000000000
Pampisford, United Kingdom
00 As of 0000
000.00
00000 0000-00-00
00000000000 000.00

000 00

te irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat
0000 000000000
Cambridge, MA
0 As of 0000
0000
00000000000 0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

SpliceBio Competitors (83)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
PhoreMost Venture Capital-Backed Pampisford, United Kingdom 00 000.00 00000000000 000.00
PAQ Therapeutics Venture Capital-Backed Cambridge, MA 0 0000 00000000000 0000
Jaguar Gene Therapy Venture Capital-Backed Lake Forest, IL 00 00000 0000000000 0 00000
Minoryx Venture Capital-Backed Barcelona, Spain 00 00000 000000 - 000 00000
Caris Life Sciences Private Equity-Backed Irving, TX 0000 00.00 00000000000 00.00
You’re viewing 5 of 83 competitors. Get the full list »

SpliceBio Patents

SpliceBio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2021241899-A1 Split inteins and their uses Pending 26-Mar-2020 000000000
CA-3175696-A1 Split inteins and their uses Pending 26-Mar-2020 000000000
EP-4127194-A1 Split inteins and their uses Pending 26-Mar-2020 000000000
US-20230116688-A1 Split inteins and their uses Pending 26-Mar-2020 000000000
EP-3885440-A1 Split inteins and their uses Pending 26-Mar-2020 C12N15/86 00
To view SpliceBio’s complete patent history, request access »

SpliceBio Executive Team (7)

Name Title Board Seat Contact Info
Miquel Vila-Perelló Ph.D Co-Founder, Chief Executive Officer, CSO & Board Member
Silvia Frutos Ph.D Co-Founder & Chief Technology Officer
David Favre Ph.D Chief Development Officer
Marc Litchfield Co-Founder & Chief Business Officer
Gerard Caelles Chief Business Officer
You’re viewing 5 of 7 executive team members. Get the full list »

SpliceBio Board Members (11)

Name Representing Role Since
Arthur Franken Gilde Healthcare Board Member 000 0000
Beat Steffen MD Novartis Venture Fund Board Member 000 0000
Edward Mathers New Enterprise Associates Board Member 000 0000
Erica Whittaker Ph.D UCB Ventures Board Member 000 0000
Jean-Philippe Combal Ph.D Self Chairman & President 000 0000
You’re viewing 5 of 11 board members. Get the full list »

SpliceBio Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

SpliceBio Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Gilde Healthcare Venture Capital Minority 000 0000 000000 0
New Enterprise Associates Venture Capital Minority 000 0000 000000 0
Novartis Venture Fund Corporate Venture Capital Minority 000 0000 000000 0
UCB Ventures Corporate Venture Capital Minority 000 0000 000000 0
Cystic Fibrosis Foundation Limited Partner 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »

SpliceBio FAQs

  • When was SpliceBio founded?

    SpliceBio was founded in 2012.

  • Who is the founder of SpliceBio?

    Miquel Vila-Perelló Ph.D, Silvia Frutos Ph.D, and Marc Litchfield are the founders of SpliceBio.

  • Who is the CEO of SpliceBio?

    Miquel Vila-Perelló Ph.D is the CEO of SpliceBio.

  • Where is SpliceBio headquartered?

    SpliceBio is headquartered in Barcelona, Spain.

  • What is the size of SpliceBio?

    SpliceBio has 39 total employees.

  • What industry is SpliceBio in?

    SpliceBio’s primary industry is Biotechnology.

  • Is SpliceBio a private or public company?

    SpliceBio is a Private company.

  • What is SpliceBio’s current revenue?

    The current revenue for SpliceBio is 00000.

  • How much funding has SpliceBio raised over time?

    SpliceBio has raised $63.3M.

  • Who are SpliceBio’s investors?

    Gilde Healthcare, New Enterprise Associates, Novartis Venture Fund, UCB Ventures, and Cystic Fibrosis Foundation are 5 of 7 investors who have invested in SpliceBio.

  • Who are SpliceBio’s competitors?

    PhoreMost, PAQ Therapeutics, Jaguar Gene Therapy, Minoryx, and Caris Life Sciences are some of the 83 competitors of SpliceBio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »